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ABSTRACT Immunity to Plasmodium falciparum malaria is slow to develop, and it is
often asserted that malaria suppresses host immunity, although this is poorly under-
stood and the molecular basis for such activity remains unknown. P. falciparum
erythrocyte membrane protein 1 (PfEMP1) is a virulence factor that plays a key role in
parasite-host interactions. We investigated the immunosuppressive effect of PfEMP1 on
monocytes/macrophages, which are central to the antiparasitic innate response. RAW
macrophages and human primary monocytes were stimulated with wild-type 3D7 or
CS2 parasites or transgenic PfEMP1-null parasites. To study the immunomodulatory
effect of PfEMP1, transcription factor activation and cytokine and chemokine re-
sponses were measured. The level of activation of NF-B was significantly lower in
macrophages stimulated with parasites that express PfEMP1 at the red blood cell
surface membrane than in macrophages stimulated with PfEMP1-null parasites. Mod-
ulation of additional transcription factors, including CREB, also occurred, resulting in
reduced immune gene expression and decreased tumor necrosis factor (TNF) and
interleukin-10 (IL-10) release. Similarly, human monocytes released less IL-1, IL-6, IL-10,
monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1
(MIP-1), MIP-1, and TNF specifically in response to VAR2CSA PfEMP1-containing
parasites than in response to PfEMP1-null parasites, suggesting that this immune
regulation by PfEMP1 is important in naturally occurring infections. These results in-
dicate that PfEMP1 is an immunomodulatory molecule that affects the activation of
a range of transcription factors, dampening cytokine and chemokine responses.
Therefore, these findings describe a potential molecular basis for immune suppres-
sion by P. falciparum.
KEYWORDS NF-B, PfEMP1, Plasmodium falciparum, cytokines, immunosuppression,
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Malaria caused by Plasmodium falciparum remains a significant global diseaseburden. During asexual blood-stage infection, when parasites invade red blood
cells (RBCs), severe disease complications can occur as a result of site-specific parasite
sequestration, the release of toxic by-products, and an unbalanced inflammatory
response (1). The immune response to malaria is complex and implicated in both
protection, involving parasite clearance and host survival (2, 3), and pathogenesis due
to excess inflammation (4–6). Innate immune cells are essential for antimalarial immu-
nity, and monocytes/macrophages play a central role in this response, consisting of
parasite phagocytosis and the release of antimicrobials (e.g., reactive oxygen/nitrogen)
and proinflammatory cytokines and chemokines (e.g., tumor necrosis factor [TNF],
interleukin-1 [IL-1], and IL-6) (5, 7, 8). Additionally, monocytes and dendritic cells
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(DCs) enhance the antiparasitic response from other cells, including  T cells and NK
cells (9, 10).
Monocytes/macrophages detect parasites through pattern recognition receptors
(PRRs) that bind pathogen-associated molecular features (11). In humans, P. falciparum
is detected by the Toll-like receptors (TLRs) TLR2, TLR4, and TLR9 and the inflam-
masomes NACHT, LRR, PYD domain-containing protein 3 (NLRP3), and absent in
melanoma 2 (AIM2) (12, 13). Recognition initiates a signaling cascade that activates
numerous transcription factors (TFs), resulting in the release of inflammatory cytokines
and the stimulation of pathogen destruction. Consequently, pathogens have devel-
oped mechanisms to evade immune detection by PRRs, including the expression of
proteins that modulate or inhibit receptor activation or signaling (13). Notably, immu-
nity to malaria develops slowly and is rapidly lost, and malaria is associated with higher
rates of secondary infections (14), suggesting that it suppresses host immunity (15, 16).
However, the underlying mechanism for this inhibition is ineffectively understood and
remains an important question in the field.
P. falciparum erythrocyte membrane protein 1 (PfEMP1) is a parasite-derived trans-
membrane protein displayed on the infected RBC (iRBC) membrane and is important
for malaria pathology and immune evasion. PfEMP1 is produced by the parasite and
subsequently transported and inserted into the host plasma membrane through
specific protein transport pathways, which require functional Maurer’s clefts and par-
asite proteins such as skeletal binding protein 1 (SBP1) and PfEMP1 trafficking protein
1 (PTP1). Genetic ablation of these proteins results in the arrest of PfEMP1 trafficking
and no PfEMP1 presentation at the host plasma membrane surface (17–19). PfEMP1 is
encoded by up to 60 variants, has a high recombination rate (20), and is monoallelically
expressed (21), providing efficient evasion of antibody detection (22). Furthermore,
PfEMP1 mediates iRBC cytoadherence to host cells by binding surface molecules such
as CD36, intercellular adhesion molecule 1 (ICAM-1), and chondroitin sulfate A (CSA)
(23, 24). This avoids parasite destruction in the spleen but also contributes to severe
disease such as cerebral and placental malaria, due to parasite sequestration in specific
organs (25–27). Although PfEMP1 has been suggested to be immunostimulatory (28,
29), we have previously shown that PfEMP1 inhibits early gamma interferon (IFN-)
release from peripheral blood mononuclear cells (PBMCs), suggesting that this protein
has immunomodulatory functions (30). Furthermore, PfEMP1 has also been reported to
inhibit DC maturation (31), although this was shown to be a dose-dependent in vitro
effect (32). Nevertheless, cell-specific molecular events associated with PfEMP1 immune
modulation have not been investigated.
As monocytes/macrophages are important early responders to malaria infection and
interact directly with parasites, we investigated the effect of PfEMP1 on these cells. We
found that PfEMP1 modulated the activation of immune-related transcription factors
and that this resulted in reduced cytokine and chemokine responses from monocytes/
macrophages that were specific for the expression of VAR2CSA PfEMP1. This indicates
that the interaction of PfEMP1 with monocytes/macrophages can result in immuno-
suppressive effects.
RESULTS
Transgenic parasite strains CS2-SBP1-KO and CS2-PTP1-KO do not have
PfEMP1 on the iRBC surface. To study the potential immunomodulatory effects of
PfEMP1 in situ, we used trophozoite-stage iRBCs from either PfEMP1-expressing strains
(CS2 wild type and 3D7 wild type) or PfEMP1-null transgenic strains. CS2 parasites
exclusively express one PfEMP1 variant (VAR2CSA) (24), whereas 3D7 parasites vary
their PfEMP1 expression (20). The CS2-SBP1-KO strain is deficient in the export of
PfEMP1 into the RBC cytoplasm and has no PfEMP1 on the surface but maintains
normal trafficking and expression of other RBC membrane-associated proteins (17, 33).
The loss of surface PfEMP1 was confirmed by iRBC trypsin treatment followed by
Western blotting with an antibody specific to the cytoplasmic acidic terminal segment
(ATS) of PfEMP1 (17–19). Trypsin degrades the extracellular domain of PfEMP1, but the
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intracellular ATS remains protected from trypsin degradation, resulting in a cleaved
band on Western blots with CS2-WT (wild-type) iRBCs but not with CS2-SBP1-KO iRBCs
(Fig. 1A). The surface PfEMP1 level was also measured by flow cytometry using an
anti-PfEMP1 antibody (Fig. 1C) (34). Comparison of CS2 with CS2-SBP1-KO parasites and
an additional PfEMP1 transport knockout (KO) strain (CS2-PTP1-KO) (18, 19) again
demonstrated the absence of PfEMP1 on the surface of the KO strains (Fig. 1D). The
3D7-UpsCR parasite strain contains the hdhfr gene that confers resistance to WR99210
downstream of the PfEMP1 promoter UpsC. Due to the allelic exclusivity of PfEMP1
expression, 3D7-UpsCR does not express PfEMP1 in the presence of WR99210 (21).
Western blot analysis of 3D7-WT and 3D7-UpsCR lysates showed that PfEMP1 expres-
sion was inhibited in 3D7-UpsCR iRBCs in the presence of WR99210 and that the
removal of WR99210 allowed some recovery of PfEMP1 expression, but this remained
substantially lower than that for 3D7-WT (Fig. 1B).
PfEMP1 modulates specific transcription factor activation in macrophages. By
using PfEMP1-null parasites, PfEMP1 was previously shown to downregulate IFN-
FIG 1 Transgenic parasite strains do not display PfEMP1 on the iRBC surface. (A) CS2-WT iRBCs, CS2-SBP1-KO iRBCs, or uRBCs were treated with 1 mg/ml trypsin
or sham treated, and lysates were probed with an antibody against the cytoplasmic acidic terminal segment (ATS) of PfEMP1. Full-length VAR2CSA PfEMP1
is 300 kDa, and cleaved surface PfEMP1 is 90 kDa. The lack of the 90-kDa band represents the absence of PfEMP1 at the surface. Full-length 300-kDa PfEMP1
is still observed, as it represents the large intracellular pool of PfEMP1, which is protected from trypsin degradation. The asterisk indicates antibody
cross-reactivity with the human spectrin protein. The Western blot is representative of results from three independent experiments. (B) 3D7-UpsCR parasites
were grown in the presence or absence of WR99210 for 2 weeks, and lysates from uRBCs, 3D7-WT iRBCs, and 3D7-UpsCR iRBCs with or without WR99210 were
probed with an anti-PfEMP1 ATS antibody. The Western blot is representative of results from three independent experiments. (C) Representative plots of CS2-WT
and CS2-SBP1-KO cultures incubated with an antibody against the extracellular domain of VAR2CSA PfEMP1 (PAM1.4) and analyzed by flow cytometry, where
ethidium bromide-positive cells were identified as iRBCs. NP, no primary antibody (used as a negative control); FSC, forward scatter. (D) Surface PfEMP1
expression levels of CS2-WT, CS2-SBP1-KO, or CS2-PTP1-KO were determined as the proportion of iRBCs that were PAM1.4 positive by flow cytometry. Error bars
represent standard deviations of data from duplicates; the graph is representative of results from three independent experiments.
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production by PBMCs (30). As monocytes/macrophages are early responders to para-
sites during infection and major sources of cytokines and chemokines, we investi-
gated potential effects of PfEMP1 on macrophage activation. To address this, we
used RAW-ELAM macrophages, which have stable luciferase expression driven by
the NF-B-responsive ELAM (E-selectin) promoter (35) and are responsive to TLR
activation (see Fig. S2 in the supplemental material). There was a significant increase in
NF-B activation in RAW-ELAM cells stimulated with the PfEMP1-null mutants CS2-
SBP1-KO (P  0.016) and CS2-PTP1-KO (P  0.039) in iRBCs compared to that with
CS2-WT (Fig. 2A and B). NF-B activation was also increased when surface PfEMP1 was
removed by trypsin treatment of wild-type CS2 (P  0.042) (Fig. 2C). To ensure that the
increase in NF-B activation was due to the absence of PfEMP1 and not due to altered
surface expression of other proteins, NF-B activation was assessed by using the
PfEMP1 knockout strain 3D7-UpsCR, which has varying PfEMP1 expression and is SBP1
and PTP1 competent (21). RAW-ELAM stimulation with 3D7-UpsCR induced significantly
higher NF-B activation than that with 3D7-WT (P  0.029) (Fig. 2D), although the
magnitude of the difference was smaller than that for CS2 parasites. Collectively, the
increased NF-B activation by PfEMP1-null iRBCs indicates that the absence of cell
surface PfEMP1 enhanced the activation of macrophages and that this was not exclu-
sive to VAR2CSA PfEMP1.
Since NF-B activation was reduced in the presence of PfEMP1, we investigated the
effect of PfEMP1 on other TFs. Subsequent experiments were performed with the
CS2-WT and CS2-SBP1-KO parasite strains, as CS2 displays a consistent PfEMP1 pheno-
type that can easily be selected for high-level expression by panning on CSA (24).
Macrophages were incubated with CS2-WT or CS2-SBP1-KO iRBCs for 4 h, and the
activation of 48 different TFs was measured by using a TF activation profiling array. Of
the 48 TFs tested, 6 consistently showed higher activity in response to CS2-SBP1-KO
FIG 2 PfEMP1-null parasites induce greater NF-B activation in macrophages than do wild-type parasites.
RAW-ELAM cells were coincubated with uRBCs, CS2-WT iRBCs, CS2-SBP1-KO iRBCs, PBS (vehicle) control,
or LPS (3.5 ng/ml; n 6) (A); uRBCs or trypsin (1 mg/ml)- or sham-treated CS2-WT iRBCs (n 4) (B); uRBC,
CS2-WT iRBCs, or CS2-PTP1-KO iRBCs (n  3) (C); and uRBCs, 3D7 iRBCs or 3D7-UpsCR iRBCs (n  4) (D).
Luciferase activity was measured after 12 h, and uRBC background levels were subtracted from iRBC
levels. Data were normalized as fold changes over WT values; the LPS level was normalized as the fold
change over the value for the vehicle-only control. Data shown are means, and error bars represent
standard errors of the means. Ratio-paired t tests were performed, and a P value of0.05 was considered
significant.
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than in response to CS2-WT (CREB, EGR, GAS/ISRE, Myb, PXR, and Stat3) in three
independent experimental repeats, of which the activities of CREB (2.3-fold; P  0.045)
and GAS/ISRE (2.8-fold; P  0.032) were statistically significant (Fig. 3). Stimulation with
CS2-SBP1-KO also showed a significant decrease in C/EBP- activation compared to
that with CS2-WT (0.3-fold; P 0.017). These data demonstrate that PfEMP1 specifically
modulates the activation of a range of TFs in macrophages.
Parasites lacking surface PfEMP1 induce differential cytokine and chemokine
responses in macrophages compared to wild-type parasites. As the presence of
PfEMP1 resulted in altered TF activation, we examined if this corresponded to a change
in the expression of immunity-associated genes. The expression levels of the cytokines
TNF, IL-10, IL-12, IL-12, and IL-18; the chemokine MIP-1 (CCL3); and the antimicro-
bial enzyme NOS2 (inducible nitric oxide synthase [iNOS]) were measured in macro-
phages after 4-, 8-, and 24-h stimulations with CS2-WT or CS2-SBP1-KO iRBCs. Com-
pared to CS2-WT, CS2-SBP1-KO induced higher expression levels of TNF at 8 h (P 
0.026), MIP-1 at 4 and 8 h (P 0.048 and P 0.008), NOS2 at 8 h (P 0.008), and IL-10
at 24 h (P  0.039). CS2-SBP1-KO also induced lower expression levels of TNF at 24 h
than those induced by CS2-WT (P  0.035) (Fig. 4A), representing a shift in the kinetics
of TNF induction, which was greater with CS2-SBP1-KO, followed by earlier downregu-
lation. No induction of IL-12, IL-12, or IL-18 expression was observed when macro-
phages were stimulated with either CS2-WT or CS2-SBP1-KO iRBCs (Fig. 4A). At the
protein level, significantly more TNF at 6 h (3.3-fold; P  0.022) and 12 h (1.6-fold; P 
0.013) and IL-10 at 24 h (2.2-fold; P  0.005) (Fig. 4B) were released in response to
CS2-SBP1-KO than in response to CS2-WT.
VAR2CSA PfEMP1 is associated with changes in cytokine and chemokine pro-
duction from human monocytes. To extend our study of the modulatory role of
PfEMP1, we investigated cytokine responses from human primary monocytes. Mono-
cytes negatively isolated from naive human blood samples (n  11 donors) were
cocultured with CS2-WT or CS2-SBP1-KO iRBCs for 12 h. Levels of IFN-2, IL-1, IL-6,
IL-10, IL-12p40, MCP-1, MIP-1, MIP-1, and TNF in the supernatant were measured by
using a Luminex multiplex enzyme-linked immunosorbent assay (ELISA). Consistent
with the effect on murine macrophages, the magnitude of the human monocyte
response to CS2-SBP1-KO iRBCs was greater than that of the response to CS2-WT (Fig.
5A). CS2-SBP1-KO iRBCs induced significantly higher levels of IL-1 (P  0.006), IL-6
FIG 3 CS2-SBP1-KO parasites induce differential activation of a range of transcription factors in macro-
phages in comparison to CS2-WT parasites. Macrophages were coincubated with CS2-WT or CS2-
SBP1-KO iRBCs for 4 h. Nuclear fractions were obtained, and activities of 48 transcription factors were
measured by using a transcription factor activation profiling array (n 3 independent experiments). Data
were normalized to the value for the general transcription factor TFIID. Transcription factors found to
have a minimum of a 2-fold change in three independent experiments are shown. Data shown are
means, and error bars represent standard errors of the means. One-sample t tests were performed, and
a P value of 0.05 was considered significant.
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FIG 4 CS2-SBP1-KO parasites induce higher expression levels of immune response genes than do CS2-WT parasites. (A)
Macrophages were stimulated with CS2-WT iRBCs (circles) or CS2-SBP1-KO iRBCs (squares) for the indicated times. RNA was
extracted, and mRNA levels of TNF, IL-10, MIP-1, NOS2, IL-12, IL-12, and IL-18 were measured by using RT-qPCR. Fold
changes over the value for the no-stimulus control are shown (n  4); ratio-paired t tests were performed, and a P value
of 0.05 was considered significant. Connecting lines indicate paired CS2-WT- and CS2-SBP1-KO-stimulated samples from the
same experimental repeat. (B) Macrophages were stimulated with uRBCs, CS2-WT iRBCs, or CS2-SBP1-KO iRBCs for indicated
times; cell culture supernatants were collected; and levels of TNF and IL-10 were measured by an ELISA. Data shown are those
after subtraction of the uRBC background (n  3) and represent means; error bars represents standard errors of the means.
Ratio-paired t tests were performed, and a P value of 0.05 was considered significant.
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(P 0.002), IL-10 (P 0.03), MCP-1 (P 0.019), MIP-1 (P 0.023), MIP-1 (P 0.029),
and TNF (P  0.023) than those induced by CS2-WT. These differences were not due to
residual WR99210 used for the selection of CS2-SBP1-KO parasites, as the treatment of
monocytes with WR99210 did not affect their cytokine response to the lipopolysac-
charide (LPS) stimulus (see Fig. S3 in the supplemental material). No significant changes
in IL-12p40 and IFN-2 levels were observed between CS2-WT and CS2-SBP1-KO. IL-18
and IL-12p70 were undetectable (data not shown). Furthermore, there was no differ-
ence in monocyte phagocytosis of CS2-WT iRBCs compared to CS2-SBP1-KO iRBCs (Fig.
5C). To investigate if monocyte cytokine responses were also modulated with addi-
tional strains, monocyte cytokine responses to 3D7-WT and 3D7-UpsCR iRBCs were
examined (n  10 donors). However, no significant differences in cytokine responses
between the two strains (Fig. 5B) were observed.
Pathways of the innate immune response and parasitic diseases are associated
with the effect of PfEMP1 on monocytes/macrophages. To gain insight into the
specific pathway(s) affected by PfEMP1, a list of the biomarkers modulated by PfEMP1
was generated (see Table S2 in the supplemental material) and interrogated by using
pathway overrepresentation analysis on the InnateDB website (http://www.innatedb
.ca/) (36). The top five signaling pathways and diseases associated with these markers
are shown in Table 1. Of note, PRR pathways, such as NOD-like receptor (NLR) and TLR
pathways, were among the top five pathways. Moreover, parasitic infections, including
malaria, were the most overrepresented diseases associated with the list, demonstrat-
ing the specificity of the analysis.
FIG 5 CS2-SBP1-KO parasites induce higher levels of cytokines and chemokines from primary human monocytes than do CS2-WT parasites. (A and B) Monocytes
from naive human donors were stimulated for 12 h with uRBCs, CS2-WT iRBCs, and CS2-SBP1-KO iRBCs (n  11 donors) (A) or uRBCs, 3D7-WT iRBCs, and
3D7-UpsCR iRBCs (n  10 donors) (B). Concentrations of cytokines and chemokines in culture supernatants were measured by a multiplex ELISA. Data shown
are those after subtraction of the uRBC background, and connecting lines indicate paired WT- and mutant iRBC-stimulated samples. Different donors were used
for the data in panels A and B. Paired t tests were performed, with a P value of 0.05 being considered significant. (C) Cells from three donors stimulated as
described above for panel A were lifted, attached to slides by cytospinning, fixed, and Field stained. Slides were analyzed by light microscopy, and cells showing
phagocytosis of iRBCs or hemozoin were counted. A minimum of 300 cells was counted under each condition; cell numbers were normalized and are displayed
as proportions of the total cells counted. Error bars represent standard errors of means. Paired t test showed no significant difference in phagocytosis rates.
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DISCUSSION
Monocytes and macrophages are crucial to the innate immune response to P.
falciparum and directly interact with iRBCs during infection. In human malaria, mono-
cytes are a major source of proinflammatory cytokines (5, 8, 37), and together with their
phagocytic and antigen-presenting capabilities, they play an important role in the
stimulation of the adaptive immune response (7). PfEMP1 is central to the host-
pathogen interaction and was previously shown to downregulate early IFN- responses
to iRBCs (30), although the mechanism of this effect was not investigated. The present
study used complementary strategies to investigate the effect of PfEMP1 on both
macrophages and primary human monocytes. In contrast to previous studies that used
bacterially expressed PfEMP1 peptides at high molecular concentrations (28, 29), we
compared wild-type parasites with transgenic parasites deficient in either PfEMP1
expression or iRBC surface display. Thus, we retained PfEMP1 in its native conformation
and at biologically relevant concentrations. Although it is possible that the trafficking
of proteins other than PfEMP1 is affected in the CS2-SBP1-KO strain, to date, disruption
of SBP1 has been shown to affect only the iRBC surface expression of PfEMP1, with no
effect on the other major parasite-derived surface proteins, KAHRP, RIFIN, STEVOR, and
PfEMP3 (17, 33, 38). Therefore, this suggests that the effects observed in this study are
PfEMP1 specific and not due to perturbations in other parasite proteins.
CS2 parasites exclusively express VAR2CSA PfEMP1, which binds to CSA and is
implicated in pregnancy-associated malaria, whereas 3D7 can vary its PfEMP1 expres-
sion (24, 26). Different PfEMP1 variants are associated with disease severity and clinical
complications, due to differential binding to host proteins (26, 39–43). Our observations
align with those of previous reports, as we discerned different downstream effects
between the two parental strains in the present study. The PfEMP1-expressing CS2-WT
and 3D7-WT strains both dampened the NF-B response compared to the correspond-
ing PfEMP1-deficient parasites, albeit the magnitude of the effect was less distinct with
3D7-WT. Furthermore, only the CS2 strain significantly affected monocyte cytokine
release. Measurement of monocyte responses following stimulation with the 3D7
strains resulted in high variation in cytokine responses. In contrast to the phenotypically
stable strain CS2, the relatively widespread distribution of responses observed with 3D7
may have been due to the altered PfEMP1 phenotype in cultured 3D7 parasites in
combination with the inherent variability of human donors. While the PfEMP1-
mediated inhibitory effect observed here may be exclusive to VAR2CSA PfEMP1, the
increased NF-B activation with 3D7-UpsCR compared to that with 3D7-WT suggests
that other PfEMP1 variants in addition to VAR2CSA result in significant effects on TF
modulation. Further work is required to determine the degree to which monocyte
activation is modulated by specific PfEMP1s and how this might be linked to cytoad-
hesion phenotypes.
VAR2CSA PfEMP1 on the iRBC surface was associated with the decreased activation
of NF-B-, CREB-, and GAS/ISRE-binding factors in macrophages and, consequently,
with reduced immunity-associated gene expression and cytokine release. These find-
ings demonstrated that the effect of PfEMP1 on TF activation translated to diminished
immune responses to iRBCs. This suggests that although relatively small changes were
observed in some cases, these signals were sufficient to distinguish meaningful effects
on target gene expression. NF-B-, CREB-, and GAS/ISRE-binding factors are activated
TABLE 1 Pathway overrepresentation analysis of PfEMP1-modulated biomarkers
interrogated against the Kyoto Encyclopedia of Genes and Genomes database
Highly associated pathway Highly associated disease
Cytokine-cytokine receptor interaction American trypanosomiasis
NOD-like receptor signaling Malaria
Toll-like receptor signaling Amoebiasis
Intestinal immunity (IgA production) African trypanosomiasis
Cytosolic DNA sensing Leishmaniasis
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by proinflammatory stimuli and upregulate the expression of immunity-associated
genes (44). Activated NF-B and CREB induce the transcription of numerous cytokines
(e.g., IL-6 and TNF), and NF-B also upregulates the expression of chemokines (e.g.,
MCP-1) and adhesion molecules (e.g., ICAM-1 and ELAM) (45). GAS/ISRE-binding factors
include the interferon regulatory factor (IRF) and signal transducer and activator of
transcription (STAT) families, which promote the expression of NOS2, IL-6, and TNF, as
well as type I interferons (46, 47). Although we could not specifically differentiate which
GAS/ISRE-binding factors were affected by VAR2CSA PfEMP1, these factors are known
mediators of immune responses (48, 49).
We also observed lower C/EBP- activation by PfEMP1-null CS2-SBP1-KO parasites
than by wild-type parasites, suggesting that VAR2CSA PfEMP1 increases C/EBP-
activation. This TF is highly expressed in the myeloid lineage and is necessary for
macrophage differentiation (50). Although a previous report showed that C/EBP- KO
macrophages had a blunted cytokine response to LPS, no studies have investigated
C/EBP- activation in response to microbes (50). Additionally, upon immune stimuli, the
downregulation of C/EBP- expression occurs concomitantly with the upregulation of
C/EBP-, which is also important for cytokine induction (51). This balance may be
crucial for the final cytokine output, and thus, the lower C/EBP- activation by PfEMP1-
null iRBCs than by the wild type could reflect a more activated/polarized macrophage
phenotype.
Monocytes are important sources of cytokines and chemokines in human malaria
infection (5, 8). We found that the inhibitory effect of VAR2CSA PfEMP1 observed in
macrophages also translated to human primary monocytes, with less IL-1, IL-6, IL-10,
MCP-1, MIP-1, MIP-1, and TNF being released in response to wild-type iRBCs than in
response to PfEMP1-null iRBCs. Since IL-12 and IL-18 levels are increased in malaria-
infected individuals (8, 52) and promote IFN- release from NK and T cells (53, 54), we
investigated whether PfEMP1 modulated IL-12 and IL-18 release. Bioactive IL-12 (IL-
12p70) is composed of p40 and p35 subunits, and IL-12p40 is produced in excess
compared to IL-12p70 (54). We detected IL-12p40 in response to iRBCs but in only 4 of
11 donors. Conversely, no IL-12p70 or IL-18 was detected following iRBC stimulation,
despite monocytes being reported to be the source of these cytokines (8). However,
released IL-12 can be difficult to detect in vitro following iRBC stimulation (8), and the
lack of detectable IL-12 and IL-18 may be due to an absence of accessory activating
signals, which were not provided in a purified monocyte/macrophage culture but
might be required for a complete immune response (53). Similarly, the induction of
mRNA expression may also require accessory cells, where IL-18 mRNA expression in
RAW cells requires exogenous IFN- (55). While it appears that IL-12 and IL-18 were not
induced in monocytes/macrophages by iRBCs in vitro, PfEMP1 may still affect these
cytokines in vivo.
We have shown for the first time that the activation of immunoregulatory TFs such
as NF-B is dampened in the presence of PfEMP1, resulting in reduced proinflammatory
responses with VAR2CSA in particular. While specific PfEMP1 variants, apart from
VAR2CSA, were not investigated separately, these observations suggest that PfEMP1
has an inhibitory role during interactions with monocytes. Inhibition of NF-B in the
regulation of immune responses is also undertaken by other parasites, such as Leish-
mania donovani and Toxoplasma gondii (56, 57). Additionally, numerous pathogens
inhibit host immune responses by modulating TLR signaling pathways (13). Since TLRs
can detect Plasmodium ligands (11), and NF-B is central to these pathways, PfEMP1
could act to inhibit TLR activation or downstream signaling. Furthermore, inflam-
masomes can detect hemozoin and associated DNA, releasing IL-1 in response (12). As
IL-1 release was decreased by PfEMP1, these pathways might also be targets for
PfEMP1-mediated modulation. In contrast, the release of IFN-2 was not affected,
indicating that the modulatory effect of PfEMP1 did not involve PRRs that upregulate
type I interferons, such as the intracellular nucleic acid-sensing cGAS/STING pathway
(12).
The proposition that PfEMP1 affects signaling from specific PRRs was supported by
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data from a bioinformatic analysis of the pathways associated with the effect of PfEMP1.
This analysis showed that TLR and NLR signaling pathways were among the most highly
associated pathways, suggesting that these pathways could represent targets for
PfEMP1 modulation. The involvement of PRR pathways was anticipated, as these
pathways have been shown to be engaged in the detection of Plasmodium antigens,
and the cytokines affected are known to be upregulated downstream of these path-
ways (11–13). Although PfEMP1 is not a known ligand for PRRs, it can interact with
other host surface receptors such as CD36 and ICAM-1 (23), and VAR2CSA in particular
binds to CSA. As TLR2 activation requires CD36 (58), this represents an attractive
candidate for mediating the modulatory effects of PfEMP1. However, CS2 parasites
express only CSA-binding VAR2CSA PfEMP1 and do not bind CD36, indicating that the
effect is not mediated through CD36. Furthermore, we did not observe differences
between phagocytosis of wild-type and PfEMP1-null CS2 iRBCs, indicating that
VAR2CSA PfEMP1-associated modulation did not result from an increased phagocyto-
sed antigen load. Instead, differential cytokine production in the presence and absence
of VAR2CSA PfEMP1 likely occurs through an interaction with an unknown surface
molecule that modulates PRR ligand binding and/or downstream signaling. The precise
molecular interactions driving this modulatory effect remain to be fully elucidated, and
in-depth investigations of all host-interacting partners of PfEMP1, especially VAR2CSA,
are needed. Furthermore, future studies to establish how different PfEMP1 variants
affect innate immune cell responses, and potential links to disease severity, will be
important to further advance our understanding of P. falciparum inhibition of immune
responses during infection.
In this study, we established a novel aspect of PfEMP1 immunosuppression through
modulations of TF activation and subsequent VAR2CSA-specific reductions of cytokine
and chemokine responses from monocytes/macrophages. As there is currently a ma-
laria vaccine strategy targeting PfEMP1 (59, 60), it is important that the various
functions of this protein are thoroughly and adequately investigated. Therefore, further
efforts to reveal the diverse roles of PfEMP1 during malaria immune responses are
warranted.
MATERIALS AND METHODS
Cell and parasite culture. Reagents were purchased from Sigma-Aldrich unless otherwise specified.
RAW-ELAM cells stably transfected with Renilla luciferase downstream of the ELAM (E-selectin) NF-B-
driven promoter were maintained in DMEM (Dulbecco’s modified Eagle medium; Gibco) with 4.5 g/liter
D-glucose, 40 mM sodium bicarbonate, 100 U/ml penicillin, and 100 g/ml streptomycin (Gibco) and 10%
heat-inactivated fetal calf serum (FCS; Gibco) at 37°C with 5% CO2.
Parasites were cultured as described previously (30). CS2 parasites with the disrupted SBP-1
(PF3D7_0501300) and PTP-1 (PF3D7_0202200 and PFB0106c) genes, referred to as CS2-SBP1-KO and
CS2-PTP1-KO, respectively, and the 3D7-UpsCR PfEMP1 knockdown strain were kindly provided by Alan
Cowman (Walter and Eliza Hall Institute) (17, 18, 21). All KO strains were cloned and cultured in the
presence of 4 nM WR99210 to maintain selective pressure. All cultures were screened for mycoplasma
contamination on a monthly basis. Supernatants taken from 2-day cultures were collected and tested for
mycoplasma by using the MycoAlert Plus kit (Lonza) according to the manufacturer’s instructions and
ascertained to be mycoplasma free.
To minimize differences in stimulation due to the variability in parasite maturation, cultures were
synchronized to a 2-h window by 5% sorbitol treatment as described previously (61). Cultures were knob
selected, and CS2 parasites were selected for binding to CSA (17).
For cell stimulations, trophozoite iRBCs (30 h postinvasion) were isolated by using a magnetically
activated cell sorting (MACS) column (minimum of 95% purity; Miltenyi Biotec). Parasites were exten-
sively washed with WR99210-free medium during isolation to ensure that no drug was present during
coincubation experiments.
Trypsin treatment of parasites. iRBCs or uninfected RBCs (uRBCs) were sham or trypsin treated as
previously described for cell stimulations (30) and lysate preparations (17).
SDS-PAGE and Western blotting. Lysates were analyzed on 3 to 8% Tris-acetate gels (NuPAGE;
Thermo Fisher Scientific) and transferred to nitrocellulose (Criterion; Bio-Rad) according to the manu-
facturer’s instructions. Membranes were blocked with 5% bovine serum albumin (BSA) in 0.05% NP-40–
Tris-buffered saline (TBSN) and probed with mouse anti-ATS PfEMP1 antibody (clone 1B/98-6H1-1)
preabsorbed to uRBC ghosts (17) and horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody
(Cell Signaling Technology) in 0.5% milk in TBSN. The anti-ATS PfEMP1 antibody has been shown to
broadly detect PfEMP1 in various parasite strains (17–19, 61).
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Fluorescence-activated cell sorter staining for VAR2CSA PfEMP1 on iRBCs. Trophozoite iRBCs
were washed and resuspended in 0.1% casein in phosphate-buffered saline (PBS). All staining solutions
were prepared in 0.1% casein–PBS and incubated for 30 min at room temperature, followed by two
washes. Samples were sequentially stained with PAM1.4 human anti-PfEMP1 antibody (1:100) (34),
biotinylated anti-human antibody and streptavidin-Alexa 633 (both at a 1:200 dilution; ThermoFisher
Scientific), and ethidium bromide (1:1,000; Bio-Rad). Samples were analyzed on a FACSCalibur instrument
(BD Biosciences). Negative-control cells were stained with all antibodies but the primary antibody and
used to set gates. PfEMP1-expressing iRBCs were identified as ethidium bromide- and Alexa 633-positive
cells. Samples were analyzed in duplicate.
NF-B luciferase assay. RAW-ELAM (35) cells (1  105 cells/well) in phenol red-free DMEM were
added to white 96-well plates and incubated for 12 to 16 h. Medium was removed, and purified iRBCs
or uRBCs (5  105 cells/well) in 100 l medium were added. Plates were incubated for a further 12 h.
BriteLite Plus luciferase reagent (100 l; PerkinElmer) was added to wells, and the wells were incubated
for 3 min. Total luminescence was measured on a Chameleon V plate reader (Hidex). Samples were
analyzed in quadruplicate, and the vehicle negative control and the Ultrapure LPS-EB (lipopolysaccharide
from E. coli 0111:B4; InvivoGen) positive control were included. Values for uRBC samples were subtracted
from those for iRBC samples. Data were normalized to represent fold changes of PfEMP1-null iRBC
stimulation over WT iRBC stimulation and of LPS stimulation over PBS stimulation, where the value for
the WT was equal to “1,” and the luciferase levels measured from PfEMP1-null cells were determined
relative to the WT signal. Independent experiments were repeated a minimum of three times on separate
days and with freshly isolated iRBCs.
Transcription factor array. RAW-ELAM cells (3  106 cells/well) were added to 6-well plates and
incubated for 12 to 16 h. CS2-WT or CS2-SBP1-KO iRBCs (15  106 cells/well) were added and incubated
for 4 h. Cells were washed to remove iRBCs, and nuclear extracts were prepared by using a nuclear
extraction kit (Signosis) according to the manufacturer’s instructions. The activation levels of 48 TFs were
measured by using TF Activation Profiling Plate Array I (Signosis). Briefly, biotin-labeled probes encoding
TF DNA-binding-site consensus sequences were incubated with 8 g of nuclear extract. Active TFs bound
their respective probes, and unbound probes were washed away. Subsequently, bound probes were
eluted and hybridized to complementary sequences on a 96-well plate. Luminescence was measured on
a Chameleon V plate reader. Values were normalized to the TFIID value, and the fold change of
CS2-SBP1-KO over CS2-WT was calculated. A 2-fold change between CS2-WT and CS2-SBP1-KO was
considered a difference. Independent experiments were repeated three times on separate days and with
freshly isolated iRBCs.
Reverse transcription-quantitative PCR (RT-qPCR). RAW-ELAM cells (3  106 cells/well) were
stimulated with iRBCs (15 106 cells/well). RNA was extracted by using an RNeasy kit (Qiagen) according
to the manufacturer’s instructions. RNA (3 g) was converted to cDNA by using a Transcriptor First Strand
cDNA kit (Roche) with oligo(dT) primers. Quantitative PCR (qPCR) was performed with 10 ng cDNA in
duplicate 12-l reaction mixtures using FastStart Universal SYBR green Master (Roche), with 45 cycles and
an annealing temperature of 60°C, on a LightCycler480 instrument (Applied Biosystems). Primers are
described in Table S1 in the supplemental material. Data were processed by using LinRegPCR (62).
Expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and -actin
values, and the fold change over unstimulated controls was calculated (63). Independent experiments
were repeated four times on separate days and with freshly isolated iRBCs.
Ethics statement. Healthy adult human donors were recruited anonymously through the Volunteer
Blood Donor Registry (approved by the human ethics committee at the Walter and Eliza Hall Institute,
project no. 13/06). All subjects provided informed written consent.
Monocyte isolation from whole blood. Exclusion criteria for study subjects (40% male; median age,
45 years [range, 24 to 65 years]) were previously known malaria infection, recent severe illness, or recent
travel to areas where malaria is endemic. PBMCs were isolated from whole blood (K2EDTA Vacutainer
tubes; BD) within 2 h of collection, as described previously (30). Monocytes were enriched by using an
EasySep Monocyte kit (Stem Cell Technologies) according to the manufacturer’s instructions. Monocyte
purity was verified by CD14 surface staining (CD14-fluorescein isothiocyanate [FITC] M5E2; BD) and
analyzed on a FACSCalibur instrument. Purity was 80% on average (range, 75 to 95%) (see Fig. S1 in
the supplemental material).
Monocyte stimulation and cytokine ELISA. Human monocytes (2 105 cells) and purified iRBCs or
uRBCs (6  105 cells) were cocultured for 12 h as described previously (30). RAW-ELAM macrophages
were stimulated with iRBCs or uRBCs as described above for the NF-B luciferase assay. LPS (3.5 ng/ml),
a positive control, and an unstimulated control were always included. Cell culture supernatants from
triplicates were pooled and tested in duplicate. A multiplex ELISA (Bio-Plex Pro assay; Bio-Rad) on a
Luminex platform and single ELISAs (ELISAkit) were done according to the manufacturers’ instructions.
For the phagocytosis assay, monocytes stimulated as described above were lifted by treatment with cold
10 mM glucose–3 mM EDTA in PBS for 10 min, attached to glass slides by cytospinning, methanol fixed,
and Field stained (Quick-Dip; Fronine). Slides were analyzed by light microscopy (magnification, 100),
and cells showing no phagocytosis or phagocytosis of iRBCs or hemozoin were counted. A minimum of
300 cells was counted under each condition.
Pathway overrepresentation analysis. Identifiers obtained from the Ensembl database (http://www
.ensembl.org/) for human and mouse genes and gene families (see Table S2 in the supplemental
material) were uploaded to InnateDB (http://www.innatedb.ca/) for pathway overrepresentation analysis
(36). The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/
pathway.html) was the source of annotated pathways. A hypergeometric algorithm and Benjamini-
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Hochberg correction were utilized automatically in the analysis to infer pathways or diseases with which
the genes in the list are known to be significantly associated.
Statistical analysis. Data were analyzed by using GraphPad Prism 6. D’Agostino-Pearson normality
tests were done for all data. For the NF-B luciferase assay, RT-qPCR, and single-cytokine ELISAs,
ratio-paired t tests were performed. For the TF activation array, one-sample t tests were performed,
where samples were compared to a hypothetical value of 1. For Luminex multiplex ELISAs, parametric
paired t tests were performed. P values of 0.05 were considered significant.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/IAI
.00447-17.
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